Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Immunotherapy and You: Gynecologic Treatment Efficacy From a Patient’s Perspective

November 2nd 2022

In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss the safety and efficacy of immunotherapy vs standard chemotherapy in patients with gynecologic cancers.

Unmet Needs and Clinical Pearls for Metastatic Endometrial Cancer

November 1st 2022

Before closing out their conversation on endometrial cancer, Kathleen Moore and David O’Malley summarize unmet needs in the field and share a few clinical pearls on managing patients with the disease.

Dr. Salani on the Role of Molecular Profiling in Endometrial Cancer Treatment

November 1st 2022

Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.

Institutional Perspectives in Cancer: Gynecologic Cancers - Chaired by Gary Altwerger, MD

October 27th 2022

Institutional Perspectives in Cancer: Gynecologic Cancers - Chaired by Gary Altwerger, MD

Immunotherapy and You: How Has Immunotherapy Changed Gynecologic Cancer Practice?

October 26th 2022

In this first episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, explain how immunotherapy has changed practice for the treatment of patients with gynecologic cancers.

Exploration of ADCs Highlights the Drive for Personalized Treatment in Ovarian Cancer

October 26th 2022

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

Emerging Biomarkers and Drug Targets in mEC

October 25th 2022

Shared insight into novel biomarkers and potential drug targets being explored for treatment of metastatic endometrial cancer.

Looking Towards the Future: Moving Targeted Therapies for mEC Into the First-Line Setting

October 25th 2022

Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.

SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer

October 20th 2022

Paul A. DiSilvestro, MD, discussed the pivotal SOLO-1 trial of maintenance olaparib in patients with BRCA-mutated ovarian cancer, updated survival data with the agent in this population, and the next steps for future research.

Ubamatamab Monotherapy Elicits Responses in Heavily Pretreated Ovarian Cancer

October 18th 2022

Ubamatamab monotherapy produced early clinical activity and an acceptable risk/benefit profile in heavily pretreated patients with ovarian cancer.

Considerations for Second-Line and Higher Treatment of Recurrent mEC

October 18th 2022

Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.

First-Line Therapy for dMMR mEC: Patient Conversations and Treatment Goals

October 18th 2022

Comprehensive discussion on patient counseling, and treatment goals, and expectations for those beginning first-line chemotherapy for dMMR metastatic endometrial cancer.

Pembrolizumab Delivers Promising Results in Advanced Clear Cell Gynecologic Cancer

October 17th 2022

Pembrolizumab monotherapy induced durable clinical outcomes in heavily pretreated patients with clear cell gynecologic cancer.

Letrozole Plus Abemaciclib Elicits Promising Responses in ER+ Endometrial Cancer

October 14th 2022

Dual inhibition with letrozole and abemaciclib displayed response and survival benefits in patients with recurrent estrogen receptor–positive endometrioid endometrial cancer.

EMA Endorses Cemiplimab Approval in Advanced Cervical Cancer

October 14th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for cemiplimab monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after platinum-based chemotherapy.

Mirvetuximab Soravtansine Generates Improvement in PROs Vs Chemotherapy in Advanced Ovarian Cancer

October 13th 2022

Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.

GX-188E Plus Pembrolizumab Proves Safe, Effective in HPV16/18+ Recurrent or Metastatic Cervical Cancer

October 13th 2022

The therapeutic DNA vaccine, GX-188E, in combination with pembrolizumab produced encouraging responses in patients with human papillomavirus 16- or 18-positive, recurrent or metastatic cervical cancer who did not respond to standard-of-care treatment.

Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status

October 12th 2022

González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.

TQB2450 Plus Anlotinib Elicits Antitumor Activity in Advanced Endometrial Cancer

October 11th 2022

The combination of TQB2450 plus anlotinib generated responses and showcased a manageable safety profile in patients with recurrent or metastatic advanced endometrial cancer, according to data from the phase 2 TQB2450 II 08 trial.

Dostarlimab Elicits Survival Benefit in dMMR/MSI-H Advanced Endometrial Cancer

October 11th 2022

Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.